Snake venom phospholipase A
Angiotensin-Converting Enzyme 2
/ metabolism
Animals
Antibody Affinity
/ drug effects
Antiviral Agents
/ pharmacology
Cell Fusion
Cell Line
Chlorocebus aethiops
Cytopathogenic Effect, Viral
/ drug effects
HEK293 Cells
Humans
Models, Molecular
Phospholipases A2
/ pharmacology
Protein Domains
/ drug effects
SARS-CoV-2
/ drug effects
Spike Glycoprotein, Coronavirus
/ metabolism
Surface Plasmon Resonance
Vero Cells
Viper Venoms
/ enzymology
Virus Attachment
/ drug effects
COVID-19 Drug Treatment
Molecular modelling
Pseudotyped SARS-CoV-2 virus
Receptor binding domain
Replication cycle
Surface plasmon resonance
Time-of-drug-addition assay
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
30
04
2021
accepted:
14
10
2021
revised:
17
09
2021
pubmed:
30
10
2021
medline:
15
12
2021
entrez:
29
10
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic caused by SARS-CoV-2 requires new treatments both to alleviate the symptoms and to prevent the spread of this disease. Previous studies demonstrated good antiviral and virucidal activity of phospholipase A
Identifiants
pubmed: 34714362
doi: 10.1007/s00018-021-03985-6
pii: 10.1007/s00018-021-03985-6
pmc: PMC8554752
doi:
Substances chimiques
Antiviral Agents
0
Spike Glycoprotein, Coronavirus
0
Viper Venoms
0
spike protein, SARS-CoV-2
0
Phospholipases A2
EC 3.1.1.4
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7777-7794Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. https://doi.org/10.1056/NEJMoa2001017
doi: 10.1056/NEJMoa2001017
pubmed: 31978945
pmcid: 7092803
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544. https://doi.org/10.1038/s41564-020-0695-z
doi: 10.1038/s41564-020-0695-z
Lefkowitz EJ, Dempsey DM, Hendrickson RC, Orton RJ, Siddell SG, Smith DB (2018) Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res 46:D708–D717. https://doi.org/10.1093/nar/gkx932
doi: 10.1093/nar/gkx932
pubmed: 29040670
Hulse JD (2020) Human coronaviruses: the deadly seven. ACTA Sci Microbiol 3:86–89. https://doi.org/10.31080/ASMI.2020.03.0612
doi: 10.31080/ASMI.2020.03.0612
Chiu SS, Chan KH, Chu KW, Kwan SW, Guan Y, Poon LLM, Peiris JSM (2005) Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis 40:1721–1729. https://doi.org/10.1086/430301
doi: 10.1086/430301
pubmed: 15909257
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
Wang K, Qiu Z, Liu J, Fan T, Liu C, Tian P, Wang Y, Ni Z, Zhang S, Luo J, Liu D, Li W (2020) Analysis of the clinical characteristics of 77 COVID-19 deaths. Sci Rep 10:16384. https://doi.org/10.1038/s41598-020-73136-7
doi: 10.1038/s41598-020-73136-7
pubmed: 33009426
pmcid: 7532142
de Souza WM, Buss LF, Candido DDS, Carrera JP, Li S, Zarebski AE, Pereira RHM, Prete CA Jr, de Souza-Santos AA, Parag KV, Belotti MCTD, Vincenti-Gonzalez MF, Messina J, da Silva Sales FC, Andrade PDS, Nascimento VH, Ghilardi F, Abade L, Gutierrez B, Kraemer MUG, Braga CKV, Aguiar RS, Alexander N, Mayaud P, Brady OJ, Marcilio I, Gouveia N, Li G, Tami A, de Oliveira SB, Porto VBG, Ganem F, de Almeida WAF, Fantinato FFST, Macário EM, de Oliveira WK, Nogueira ML, Pybus OG, Wu CH, Croda J, Sabino EC, Faria NR (2020) Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav 4:856–865. https://doi.org/10.1038/s41562-020-0928-4
doi: 10.1038/s41562-020-0928-4
pubmed: 32737472
Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S, Vincent SP, Soumillion P, Alsteens D (2020) Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun 11:1–10. https://doi.org/10.1038/s41467-020-18319-6
doi: 10.1038/s41467-020-18319-6
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12:eabb5883. https://doi.org/10.1126/scitranslmed.abb5883
doi: 10.1126/scitranslmed.abb5883
pubmed: 32253226
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY (2016) Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 15:327–347. https://doi.org/10.1038/nrd.2015.37
doi: 10.1038/nrd.2015.37
pubmed: 26868298
pmcid: 7097181
Khatoon F, Prasad K, Kumar V (2020) Neurological manifestations of COVID-19: available evidences and a new paradigm. J Neurovirol 26:619–630. https://doi.org/10.1007/s13365-020-00895-4
doi: 10.1007/s13365-020-00895-4
pubmed: 32839951
Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Böddinghaus B, Götsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild MJGT, Kann G, Wolf T, Gottschalk R, Ciesek S (2020) Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med 382:1278–1280. https://doi.org/10.1056/NEJMc2001899
doi: 10.1056/NEJMc2001899
pubmed: 32069388
pmcid: 7121749
Schöni R (2005) The use of snake venom-derived compounds for new functional diagnostic test kits in the field of haemostasis. Pathophysiol Haemost Thromb 34:234–240. https://doi.org/10.1159/000092430
doi: 10.1159/000092430
pubmed: 16707934
Rivero JVR, de Castro FOF, Stival AS, Magalhães MR, Carmo Filho JR, Pfrimer IAH (2011) Mechanisms of virus resistance and antiviral activity of snake venoms. J Venom Anim Toxins Incl Trop Dis 17:387–393. https://doi.org/10.1590/S1678-91992011000400005
doi: 10.1590/S1678-91992011000400005
Koh CY, Kini RM (2012) From snake venom toxins to therapeutics—cardiovascular examples. Toxicon 59:497–506. https://doi.org/10.1016/j.toxicon.2011.03.017
doi: 10.1016/j.toxicon.2011.03.017
pubmed: 21447352
Calderon LA, Sobrinho JC, Zaqueo KD, de Moura AA, Grabner AN, Mazzi MV, Marcussi S, Nomizo A, Fernandes CF, Zuliani JP, Carvalho BM, da Silva SL, Stábeli RG, Soares AM (2014) Antitumoral activity of snake venom proteins: new trends in cancer therapy. Biomed Res Int 2014:203639. https://doi.org/10.1155/2014/203639
doi: 10.1155/2014/203639
pubmed: 24683541
pmcid: 3943284
da Mata ÉCG, Mourão CBF, Rangel M, Schwartz EF (2017) Antiviral activity of animal venom peptides and related compounds. J Venom Anim Toxins Incl Trop Dis 23:3. https://doi.org/10.1186/s40409-016-0089-0
doi: 10.1186/s40409-016-0089-0
pubmed: 28074089
pmcid: 5217322
Shimizu JF, Pereira CM, Bittar C, Batista MN, Campos GRF, da Silva S, Cintra ACO, Zothner C, Harris M, Sampaio SV, Aquino VH, Rahal P, Jardim ACG (2017) Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle. PLoS ONE 12:e0187857. https://doi.org/10.1371/journal.pone.0187857
doi: 10.1371/journal.pone.0187857
pubmed: 29141010
pmcid: 5687739
El-Aziz TMA, Soares AG, Stockand JD (2019) Snake venoms in drug discovery: valuable therapeutic tools for life saving. Toxins (Basel) 11:564. https://doi.org/10.3390/toxins11100564
doi: 10.3390/toxins11100564
Ghosh A, Roy R, Nandi M, Mukhopadhyay A (2019) Scorpion venom-toxins that aid in drug development: a review. Int J Pept Res Ther 25:27–37. https://doi.org/10.1007/s10989-018-9721-x
doi: 10.1007/s10989-018-9721-x
pubmed: 32214927
Herzig V, Cristofori-Armstrong B, Israel MR, Nixon SA, Vetter I, King GF (2020) Animal toxins—Nature’s evolutionary-refined toolkit for basic research and drug discovery. Biochem Pharmacol 181:114096. https://doi.org/10.1016/j.bcp.2020.114096
doi: 10.1016/j.bcp.2020.114096
pubmed: 32535105
pmcid: 7290223
Gutiérrez JM, Lomonte B (2013) Phospholipases A2: unveiling the secrets of a functionally versatile group of snake venom toxins. Toxicon 62:27–39. https://doi.org/10.1016/j.toxicon.2012.09.006
doi: 10.1016/j.toxicon.2012.09.006
pubmed: 23025922
Kini RM (2000) Snake venom phospholipase A2 enzymes in cell biology. In: Rochat H, Martin-Eauclaire MF (eds) Animal toxins methods and tools in biosciences and medicine. Birkhäuser, Basel, pp 304–318. https://doi.org/10.1007/978-3-0348-8466-2_19
doi: 10.1007/978-3-0348-8466-2_19
Berg OG, Gelb MH, Tsai MD, Jain MK (2001) Interfacial enzymology: the secreted phospholipase A2-paradigm. Chem Rev 101:2613–2653. https://doi.org/10.1021/cr990139w
doi: 10.1021/cr990139w
pubmed: 11749391
Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G (2011) Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 111:6130–6185. https://doi.org/10.1021/cr200085w
doi: 10.1021/cr200085w
pubmed: 21910409
pmcid: 3196595
de Paula R, Castro H, Rodrigues C, Melo P, Fuly A (2009) Structural and pharmacological features of phospholipases A2 from snake venoms. Protein Pept Lett 16:899–907. https://doi.org/10.2174/092986609788923365
doi: 10.2174/092986609788923365
pubmed: 19689416
Muller VDM, Russo RR, Oliveira Cintra AC, Sartim MA, De Melo A-P, Figueiredo LTM, Sampaio SV, Aquino VH (2012) Crotoxin and phospholipases A 2 from Crotalus durissus terrificus showed antiviral activity against dengue and yellow fever viruses. Toxicon 59:507–515. https://doi.org/10.1016/j.toxicon.2011.05.021
doi: 10.1016/j.toxicon.2011.05.021
pubmed: 21723310
Kim J-O, Chakrabarti BK, Guha-Niyogi A, Louder MK, Mascola JR, Ganesh L, Nabel GJ (2007) Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol 81:1444–1450. https://doi.org/10.1128/JVI.01790-06
doi: 10.1128/JVI.01790-06
pubmed: 17093191
Drayton HA (1961) Inactivation of Rous virus by phospholipase A. Nature 192:896. https://doi.org/10.1038/192896a0
doi: 10.1038/192896a0
pubmed: 13887755
Mitsuishi M, Masuda S, Kudo I, Murakami M (2006) Group V and X secretory phospholipase A2 prevents adenoviral infection in mammalian cells. Biochem J 393:97–106. https://doi.org/10.1042/BJ20050781
doi: 10.1042/BJ20050781
pubmed: 16146426
Kohn A, Klibansky C (1967) Studies on the inactivation of cell-fusing property of newcastle disease virus by phospholipase A. Virology 31:385–388. https://doi.org/10.1016/0042-6822(67)90183-3
doi: 10.1016/0042-6822(67)90183-3
pubmed: 6021100
Santos IA, Shimizu JF, de Oliveira DM, Martins DOS, Cardoso-Sousa L, Cintra ACO, Aquino VH, Sampaio SV, Nicolau-Junior N, Sabino-Silva R, Merits A, Harris M, Jardim ACG (2021) Chikungunya virus entry is strongly inhibited by phospholipase A2 isolated from the venom of Crotalus durissus terrificus. Sci Rep 11:8717. https://doi.org/10.1038/s41598-021-88039-4
doi: 10.1038/s41598-021-88039-4
pubmed: 33888774
pmcid: 8062466
Kruglova N, Siniavin A, Gushchin V, Mazurov D (2021) Different neutralization sensitivity of SARS-CoV-2 cell-to-cell and cell-free modes of infection to convalescent sera. Viruses 13:1133. https://doi.org/10.3390/v13061133
doi: 10.3390/v13061133
pubmed: 34204732
pmcid: 8231521
Tran TV, Siniavin AE, Hoang AN, Le MTT, Pham CD, Phung TV, Nguyen KC, Ziganshin RH, Tsetlin VI, Weng CF, Utkin YN (2019) Phospholipase A2 from krait Bungarus fasciatus venom induces human cancer cell death in vitro. PeerJ 7:e8055. https://doi.org/10.7717/peerj.8055
doi: 10.7717/peerj.8055
pubmed: 31824756
pmcid: 6896944
Tsai IH, Wang YM, Cheng AC, Starkov V, Osipov A, Nikitin I, Makarova Y, Ziganshin R, Utkin Y (2011) cDNA cloning, structural, and functional analyses of venom phospholipases A2 and a Kunitz-type protease inhibitor from steppe viper Vipera ursinii renardi. Toxicon 57:332–341. https://doi.org/10.1016/j.toxicon.2010.12.012
doi: 10.1016/j.toxicon.2010.12.012
pubmed: 21185324
Ramazanova AS, Zavada LL, Starkov VG, Kovyazina IV, Subbotina TF, Kostyukhina EE, Dementieva IN, Ovchinnikova TV, Utkin YN (2008) Heterodimeric neurotoxic phospholipases A2-The first proteins from venom of recently established species Vipera nikolskii: Implication of venom composition in viper systematics. Toxicon 51:524–537. https://doi.org/10.1016/j.toxicon.2007.11.001
doi: 10.1016/j.toxicon.2007.11.001
pubmed: 18083205
Radvanyi F, Jordan L, Russo-Marie F, Bon C (1989) A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin. Anal Biochem 177:103–109. https://doi.org/10.1016/0003-2697(89)90022-5
doi: 10.1016/0003-2697(89)90022-5
pubmed: 2742139
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. https://doi.org/10.1016/0022-1759(83)90303-4
doi: 10.1016/0022-1759(83)90303-4
Luo Y, Deng X, Cheng F, Li Y, Qiu J (2013) SMC1-mediated intra-S-phase arrest facilitates bocavirus DNA replication. J Virol 87:4017–4032. https://doi.org/10.1128/JVI.03396-12
doi: 10.1128/JVI.03396-12
pubmed: 23365434
pmcid: 3624210
Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z, Shuxiang H, Jun D, Xiaobo L, Xiaotao H, Lin W, Nanshan Z, Zifeng Y (2020) Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 156:104761. https://doi.org/10.1016/j.phrs.2020.104761
doi: 10.1016/j.phrs.2020.104761
pubmed: 32205232
pmcid: 7102548
De Meyer S, Bojkova D, Cinatl J, Van Damme E, Buyck C, Van Loock M, Woodfall B, Ciesek S (2020) Lack of antiviral activity of darunavir against SARS-CoV-2. Int J Infect Dis 97:7–10. https://doi.org/10.1016/j.ijid.2020.05.085
doi: 10.1016/j.ijid.2020.05.085
pubmed: 32479865
pmcid: 7258847
Wang G, Yang ML, Duan ZL, Liu FL, Jin L, Long CB, Zhang M, Tang XP, Xu L, Li YC, Kamau PM, Yang L, Liu HQ, Xu JW, Chen JK, Zheng YT, Peng XZ, Lai R (2021) Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. Cell Res 31:17–24. https://doi.org/10.1038/s41422-020-00450-0
doi: 10.1038/s41422-020-00450-0
pubmed: 33262453
Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoins. Am J Epidemiol 27:493–497
doi: 10.1093/oxfordjournals.aje.a118408
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L (2019) A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv 5:eaav4580. https://doi.org/10.1126/sciadv.aav4580
doi: 10.1126/sciadv.aav4580
pubmed: 30989115
pmcid: 6457931
Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30:343–355. https://doi.org/10.1038/s41422-020-0305-x
doi: 10.1038/s41422-020-0305-x
pubmed: 32231345
pmcid: 7104723
Fenard D, Lambeau G, Maurin T, Lefebvre JC, Doglio A (2001) A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Pharmacol 60:341–347. https://doi.org/10.1124/mol.60.2.341
doi: 10.1124/mol.60.2.341
pubmed: 11455021
Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296–W303. https://doi.org/10.1093/nar/gky427
doi: 10.1093/nar/gky427
pubmed: 29788355
pmcid: 6030848
Banumathi S, Rajashankar KR, Nötzel C, Aleksiev B, Singh TP, Genov N, Betzel C (2001) Structure of the neurotoxic complex vipoxin at 1.4 A resolution. Acta Crystallogr D Biol Crystallogr 57:1552–1559. https://doi.org/10.1107/s0907444901013543
doi: 10.1107/s0907444901013543
pubmed: 11679719
Ramírez-Aportela E, López-Blanco JR, Chacón P (2016) FRODOCK 2.0: fast protein-protein docking server. Bioinformatics 32:2386–2388. https://doi.org/10.1093/bioinformatics/btw141
doi: 10.1093/bioinformatics/btw141
pubmed: 27153583
Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ (2020) Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588:327–330. https://doi.org/10.1038/s41586-020-2772-0
doi: 10.1038/s41586-020-2772-0
pubmed: 32942285
pmcid: 7116727
Leman JK, Weitzner BD, Lewis SM et al (2020) Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat Methods 17:665–680. https://doi.org/10.1038/s41592-020-0848-2
doi: 10.1038/s41592-020-0848-2
pubmed: 32483333
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612. https://doi.org/10.1002/jcc.20084
doi: 10.1002/jcc.20084
pubmed: 15264254
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, Sheffield COVID-19 Genomics Group, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC (2020) Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182:812-827.e19. https://doi.org/10.1016/j.cell.2020.06.043
doi: 10.1016/j.cell.2020.06.043
pubmed: 32697968
pmcid: 7332439
Kemp SA, Datir RP, Collier DA, Ferreira IATM, Carabelli A, Harvey W, Robertson DL, Gupta RK (2020) Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ∆H69/V70. bioRxiv. https://doi.org/10.1101/2020.12.14.422555
doi: 10.1101/2020.12.14.422555
Liu Z, Zheng H, Lin H, Li M, Yuan R, Peng J, Xiong Q, Sun J, Li B, Wu J, Yi L, Peng X, Zhang H, Zhang W, Hulswit RJG, Loman N, Rambaut A, Ke C, Bowden TA, Pybus OG, Lu J (2020) Identification of common deletions in the spike protein of severe acute respiratory syndrome coronavirus 2. J Virol 94:e00790-e820. https://doi.org/10.1128/JVI.00790-20
doi: 10.1128/JVI.00790-20
pubmed: 32571797
pmcid: 7431800
Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. https://doi.org/10.1101/2020.12.21.20248640
doi: 10.1101/2020.12.21.20248640
pubmed: 33236025
pmcid: 7685338
Kruse RL (2020) Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research 9:72. https://doi.org/10.12688/f1000research.22211.2
doi: 10.12688/f1000research.22211.2
pubmed: 32117569
pmcid: 7029759
Kumar M, Al Khodor S (2020) Pathophysiology and treatment strategies for COVID-19. J Transl Med 18:353. https://doi.org/10.1186/s12967-020-02520-8
doi: 10.1186/s12967-020-02520-8
pubmed: 32933536
pmcid: 7491044
Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, Pochtovyi AA, Shidlovskaya EV, Kuznetsova NA, Burgasova OA, Kolobukhina LV, Iliukhina AA, Kovyrshina AV, Botikov AG, Kuzina AV, Grousova DM, Tukhvatulin AI, Shcheblyakov DV, Zubkova OV, Karpova OV, Voronina OL, Ryzhova NN, Aksenova EI, Kunda MS, Lioznov DA, Danilenko DM, Komissarov AB, Tkachuck AP, Logunov DY, Gintsburg AL (2021) Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 variants. Vaccines 9:779. https://doi.org/10.3390/vaccines9070779
doi: 10.3390/vaccines9070779
pubmed: 34358195
pmcid: 8310330
Muller VD, Soares RO, dos Santos NN Jr, Trabuco AC, Cintra AC, Figueiredo LT, Caliri A, Sampaio SV, Aquino VH (2014) Phospholipase A2 isolated from the venom of Crotalus durissus terrificus inactivates dengue virus and other enveloped viruses by disrupting the viral envelope. PLoS ONE 9:e112351. https://doi.org/10.1371/journal.pone.0112351
doi: 10.1371/journal.pone.0112351
pubmed: 25383618
pmcid: 4226559
Brenes H, Loría GD, Lomonte B (2020) Potent virucidal activity against Flaviviridae of a group IIA phospholipase A
doi: 10.1016/j.biologicals.2019.12.002.40
pubmed: 31839332
Lenard J (2008) Viral membranes. In: Mahy BWJ, Van Regenmortel MHV (eds) Encyclopedia of virology, 3rd edn. Academic Press, pp 308–314. https://doi.org/10.1016/B978-012374410-4.00530-6
doi: 10.1016/B978-012374410-4.00530-6
Lorizate M, Kräusslich HG (2011) Role of lipids in virus replication. Cold Spring Harb Perspect Biol 3:1–20. https://doi.org/10.1101/cshperspect.a004820
doi: 10.1101/cshperspect.a004820
Alekseeva AS, Tretiakova DS, Chernikov VP, Utkin YN, Molotkovsky JG, Vodovozova EL, Boldyrev IA (2017) Heterodimeric V. nikolskii phospholipases A2 induce aggregation of the lipid bilayer. Toxicon 133:169–179. https://doi.org/10.1016/j.toxicon.2017.05.015
doi: 10.1016/j.toxicon.2017.05.015
pubmed: 28528175
Gunther-Ausborn S, Praetor A, Stegmann T (1995) Inhibition of influenza-induced membrane fusion by lysophosphatidylcholine. J Biol Chem 270:29279–29285. https://doi.org/10.1074/jbc.270.49.29279
doi: 10.1074/jbc.270.49.29279
pubmed: 7493959
Günther-Ausborn S, Stegmann T (1997) How lysophosphatidylcholine inhibits cell-cell fusion mediated by the envelope glycoprotein of human immunodeficiency virus. Virology 235:201–208. https://doi.org/10.1006/viro.1997.8699
doi: 10.1006/viro.1997.8699
pubmed: 9281499
Yan B, Chu H, Yang D, Sze KH, Lai PM, Yuan S, Shuai H, Wang Y, Kao RY, Chan JF, Yuen KY (2019) Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication. Viruses 11:73. https://doi.org/10.3390/v11010073
doi: 10.3390/v11010073
pmcid: 6357182
Praznikar ZJ, Kovacic L, Rowan EG, Romih R, Rusmini P, Poletti A, Krizaj I, Pungercar J (2008) A presynaptically toxic secreted phospholipase A2 is internalized into motoneuron-like cells where it is rapidly translocated into the cytosol. Biochim Biophys Acta 1783:1129–1139. https://doi.org/10.1016/j.bbamcr.2008.01.011
doi: 10.1016/j.bbamcr.2008.01.011
pubmed: 18261469
da Lomeo RS, Gonçalves AP, da Silva CN, de Paula AT, Costa Santos DO, Fortes-Dias CL, Gomes DA, de Lima ME (2014) Crotoxin from Crotalus durissus terrificus snake venom induces the release of glutamate from cerebrocortical synaptosomes via N and P/Q calcium channels. Toxicon 85:5–16. https://doi.org/10.1016/j.toxicon.2014.04.008
doi: 10.1016/j.toxicon.2014.04.008
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292.e6. https://doi.org/10.1016/j.cell.2020.02.058
doi: 10.1016/j.cell.2020.02.058
pubmed: 32155444
pmcid: 7102599
Hoffmann M, Kleine-Weber H, Pöhlmann S (2020) A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell 78:779-784.e5. https://doi.org/10.1016/j.molcel.2020.04.022
doi: 10.1016/j.molcel.2020.04.022
pubmed: 32362314
pmcid: 7194065
Li C, Dowd CS, Zhang W, Chaiken IM (2001) Phage randomization in a charybdotoxin scaffold leads to CD4-mimetic recognition motifs that bind HIV-1 envelope through non-aromatic sequences. J Pept Res 57:507–518. https://doi.org/10.1046/j.1397-002x.2001.00876.x
doi: 10.1046/j.1397-002x.2001.00876.x
pubmed: 11437954